Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OrienX010 vs Dacarbazine in Melanoma
CTR20171275Phase 2Active
- Sponsor
- OrienGene Biotechnology
- Start
- Dec 2017
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of orienx010 in melanoma, sponsored by OrienGene Biotechnology. Started Dec 2017; status: active.
02
Drugs
orienx010
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20171275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171275.